MS12 Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

SEHN L., HERRERA A. F., MATASAR M. J., KAMDAR M., MCMİLLAN A., KİM T. M., ...Daha Fazla

ASH 2017, 6 - 14 Aralık 2017, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Ankara Üniversitesi Adresli: Evet